Development of Styrylquinoline Integrase Inhibitors

HIV-1 Integrase: Mechanism and Inhibitor Design

Volumn , Issue , 2011, Pages 325-339

  Mouscadet, Jean François ^a   Deprez, Eric ^a   Desmaele, Didier ^b   D'Angelo, Jean ^b  

^a Ecole Normale Superieure de Cachan   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Cell culture antiviral activity; Styrylquinoline integrase inhibitors; Styrylquinolines, activity relationships

Indexed keywords

EID: 84878140261     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118015377.ch22     Document Type: Chapter

References (56)

1. Lewinski, M. K.; Bushman, F. D. Retroviral DNA integration-Mechanism and consequences. Adv. Genet. 2005, 55, 147-181
2. Hazuda, D. J.; Felock, P.;Witmer, M.;Wolfe, A.; Stillmock, K.; Grobler, J.A.;Espeseth,A.;Gabryelski, L.; Schleif,W.;Blau,C.; Miller,M.D. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells [In Process Citation]. Science 2000, 287, 646-650
3. Malet, I.; Delelis, O.; Valantin, M. A.; Montes, B.; Soulie, C.; Wirden, M.; Tchertanov, L.; Peytavin, G.; Reynes, J.; Mouscadet, J. F.; Katlama, C.; Calvez, V.; Marcelin, A. G. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob. Agents Chemother. 2008, 52, 1351-1358
4. Wolfenden, R.; Ridgway, C.; Young, G. Spontaneous hydrolysis of ionized phosphate monoesters and diesters and the proficiencies of phosphatases and phosphodiesterases as catalysts. J. Am. Chem. Soc. 2007, 120, 833-834
5. Williams, N. H.; Takasaki, B.;Wall, M.; Chin, J. Structure and nuclease activity of simple dinuclear metal complexes: Quantitative dissection of the role of metal ions. Acc. Chem. Res. 1999, 32, 485-493
6. Beese, L. S.; Steitz, T. A. Structural basis for the 30-50 exonuclease activity of Escherichia coli DNA polymerase I: A two metal ion mechanism. EMBO J. 1991, 10, 25-33
7. Blasko, A.; Bruice, T. C. Recent studies of nucleophilic, general-acid, and metal ion catalysis of phosphate diester hydrolysis. Acc. Chem. Res. 1999, 32, 475-484
8. Horton, N. C.; Perona, J. J. Making the most of metal ions. Nat. Struct. Biol. 2001, 8, 290-293
9. Pingoud, A.; Jeltsch, A. Structure and function of type II restriction endonucleases. Nucleic Acids Res. 2001, 29, 3705-3727
10. Sechi, M.; Bacchi, A.; Carcelli, M.; Compari, C.; Duce, E.; Fisicaro, E.; Rogolino, D.; Gates, P.; Derudas, M.; Al-Mawsawi, L. Q.; Neamati, N. From ligand to complexes: Inhibition of human immunodeficiency virus type 1 integrase by beta-diketo acid metal complexes. J. Med. Chem. 2006, 49, 4248-4260
11. Marchand, C.; Johnson, A. A.; Karki, R. G.; Pais, G. C.; Zhang, X.; Cowansage, K.; Patel, T. A.; Nicklaus, M. C.;Burke, T. R., Jr.,; Pommier, Y. Metal-dependent inhibition of HIV-1 integrase by beta-diketo acids and resistance of the soluble double-mutant (F185K/C280S). Mol. Pharmacol. 2003, 64, 600-609
12. Goldgur, Y.; Dyda, F.; Hickman, A. B.; Jenkins, T. M.; Craigie, R.; Davies, D. R. Three new structures of the core domain of HIV-1 integrase: An active site that binds magnesium. Proc. Natl. Acad. Sci. USA 1998, 95, 9150-9154
13. Lins, R. D.; Straatsma, T. P.; Briggs, J. M. Similarities in the HIV-1 and ASV integrase active sites upon metal cofactor binding. Biopolymers 2000, 53, 308-315
14. Bujacz, G.; Alexandratos, J.; Wlodawer, A.; Merkel, G.; Andrake, M.; Katz, R. A.; Skalka, A. M. Binding of different divalent cations to the active site of avian sarcoma virus integrase and their effects on enzymatic activity. J. Biol. Chem. 1997, 272, 18161-18168
15. Pommier, Y.; Johnson, A. A.; Marchand, C. Integrase inhibitors to treat HIV/AIDS. Nat. Rev. Drug Discov. 2005, 4, 236-248
16. Mekouar, K.; Mouscadet, J. F.; Desmaele, D.; Subra, F.; Leh, H.; Savoure, D.; Auclair, C.; d'Angelo, J. Styrylquinoline derivatives: A new class of potent HIV-1 integrase inhibitors that block HIV-1 replication in CEM cells. J. Med. Chem. 1998, 41, 2846-2857
17. Zouhiri, F. Unpublished work, 2007
18. Polanski, J.; Niedbala, H.; Musiol, R.; Podeszwa, B.; Tabak, D.; Palka, A.; Mencel, A.; Finster, J.; Mouscadet, J. F.; Le Bret, M. 5-Hydroxy-6-quinaldic acid as a novel molecular scaffold for HIV-1 integrase inhibitors. Lett. Drug Des. & Discov. 2006, 3, 175-178
19. Zhuang, L.; Wai, J. S.; Embrey, M. W.; Fisher, T. E.; Egbertson, M. S.; Payne, L. S.; Guare, J. P., Jr.; Vacca, J. P.; Hazuda, D. J.; Felock, P. J.; Wolfe, A. L.; Stillmock, K. A.; Witmer, M. V.; Moyer, G.; Schleif, W. A.; Gabryelski, L. J.; Leonard, Y. M.; Lynch, J. J., Jr.; Michelson, S. R.; Young, S. D. Design and synthesis of 8-hydroxy-[1,6]naphthyridines as novel inhibitors of HIV-1 integrase in vitro and in infected cells. J. Med. Chem. 2003, 46, 453-456
20. Guare, J. P.; Wai, J. S.; Gomez, R. P.; Anthony, N. J.; Jolly, S. M.; Cortes, A. R.; Vacca, J. P.; Felock, P. J.; Stillmock, K. A.; Schleif,W. A.; Moyer, G.; Gabryelski, L. J.; Jin, L. X.; Chen, I. W.; Hazuda, D. J.; Young, S. D. A series of 5-aminosubstituted 4-fluorobenzyl-8-hydroxy-[1,6]naphthyridine-7-carboxamide HIV-1 integrase inhibitors. Bioorg. Med. Chem. Lett. 2006, 16, 2900-2904
21. Polanski, J.; Zouhiri, F.; Jeanson, L.; Desmaele, D.; d'Angelo, J.; Mouscadet, J. F.; Gieleciak, R.; Gasteiger, J.; Le, B. M. Use of the Kohonen neural network for rapid screening of ex vivo anti-HIV activity of styrylquinolines. J. Med. Chem. 2002, 45, 4647-4654
22. Normand-Bayle, M.; Benard, C.; Zouhiri, F.; Mouscadet, J. F.; Leh, H.; Thomas, C. M.; Mbemba, G.; Desmaele, D.; d'Angelo, J. New HIV-1 replication inhibitors of the styryquinoline class bearing aroyl/acyl groups at the C-7 position: Synthesis and biological activity. Bioorg. Med. Chem. Lett. 2005, 15, 4019-4022
23. Normand-Bayle, M. Synthe'se et activité biologique de nouvelles styrylquinoléines inhibitrices de l'intégrase du VIH-1. Universit-e Paris-Sud. 2004
24. Yoo, H.; Lee, J. Y.; Park, J. H.; Chung, B. Y.; Lee, Y. S. Synthesis of styrylbenzofuran derivatives as styrylquinolines analogues for HIV-1 integrase inhibitors. Il Farmaco 2003, 58, 1243-1250
25. Zouhiri, F.; Danet, M.; Benard, C.; Normand-Bayle, M.; Mouscadet, J. F.; Leh, H.; Marie Thomas, C.; Mbemba, G.; d'Angelo, J.; Desmaele, D. HIV-1 replication inhibitors of the styrylquinoline class: Introduction of an additional carboxyl group at the C-5 position of the quinoline. Tetrahedron Lett. 2005, 46, 2201-2205
26. Zouhiri, F.; Mouscadet, J. F.; Mekouar, K.; Desmaele, D.; Savoure, D.; Leh, H.; Subra, F.; Le Bret, M.; Auclair, C.; d'Angelo, J. Structure-activity relationships and binding mode of styrylquinolines as potent inhibitors of HIV-1 integrase and replication of HIV-1 in cell culture. J. Med. Chem. 2000, 43, 1533-1540
27. Sliman, F. Unpublished work, 2007
28. Benard, C.; Zouhiri, F.; Normand-Bayle, M.; Danet, M.; Desmaele, D.; Leh, H.; Mouscadet, J. F.; Mbemba, G.; Thomas, C. M.; Bonnenfant, S.; Le, B. M.; d'Angelo, J. Linker-modified quinoline derivatives targeting HIV-1 integrase: Synthesis and biological activity. Bioorg. Med. Chem. Lett. 2004, 14, 2473-2476
29. Courcot, B.; Firley, D.; Fraisse, B.; Becker, P.; Gillet, J. M.; Pattison, P.; Chernyshov, D.; Sghaier,M.; Zouhiri, F.; Desmaele, D.; d'Angelo, J.; Bonhomme, F.; Geiger, S.; Ghermani, N. E. Crystal and electronic structures of magnesium(II), copper(II), and mixed magnesium(II)-copper(II) complexes of the quinoline half of styrylquinoline-type HIV-1 integrase inhibitors. J. Phys. Chem. B 2007, 111, 6042-6050
30. Ouali, M.; Laboulais, C.; Leh, H.; Gill, D.; Xhuvani, E.; Zouhiri, F.; Desmaele, D.; d'Angelo, J.; Auclair, C.; Mouscadet, J. F.; Le Bret, M. Tautomers of styrylquinoline derivatives containing a methoxy substituent: Computation of their population in aqueous solution and their interaction with RSV integrase catalytic core [In Process Citation]. Acta Biochim. Pol. 2000, 47, 11-22
31. Ouali, M.; Laboulais, C.; Leh, H.; Gill, D.; Desmaele, D.; Mekouar, K.; Zouhiri, F.; d'Angelo, J.; Auclair, C.; Mouscadet, J. F.; Le Bret, M. Modeling of the inhibition of retroviral integrases by styrylquinoline derivatives. J. Med. Chem. 2000, 43, 1949-1957
32. Ma, X. H.; Zhang, X. Y.; Tan, J. J.; Chen, W. Z.; Wang, C. X. Exploring binding mode for styrylquinoline HIV-1 integrase inhibitors using comparative molecular field analysis and docking studies. Acta Pharmacol. Sin. 2004, 25, 950-958
33. Breneman, C. M.; Wiberg, K. B. Determining atom-centered monopoles from molecular electrostatic potentials. The need for high sampling density in formamide conformational analysis. J. Comput. Chem. 1990, 11, 361-373
34. Deprez, E.; Barbe, S.; Kolaski, M.; Leh, H.; Zouhiri, F.; Auclair, C.; Brochon, J. C.; Le Bret, M.; Mouscadet, J. F. Mechanism of HIV-1 integrase inhibition by styrylquinoline derivatives in vitro. Mol. Pharmacol. 2004, 65, 85-98
35. Firley, D.; Courcot, B.; Gillet, J. M.; Fraisse, B.; Zouhiri, F.; Desmaele, D.; d'Angelo, J.; Ghermani, N. E. Experimental/ theoretical electrostatic properties of a styrylquinoline-type HIV-1 integrase inhibitor and its progenitors. J. Phys. Chem. B 2006, 110, 537-547
36. Esposito, D.; Craigie, R. Sequence specificity of viral end DNA binding by HIV-1 integrase reveals critical regions for protein-DNA interaction. EMBO J. 1998, 17, 5832-5843
37. Jenkins, T. M.; Esposito, D.; Engelman, A.; Craigie, R. Critical contacts between HIV-1 integrase and viral DNA identified by structure-based analysis and photo-crosslinking. EMBO J. 1997, 16, 6849-6859
38. Mazumder, A.; Neamati, N.; Pilon, A. A.; Sunder, S.; Pommier, Y. Chemical trapping of ternary complexes of human immunodeficiency virus type 1 integrase, divalent metal, and DNA substrates containing an abasic site. Implications for the role of lysine 136 in DNA binding. J. Biol. Chem. 1996, 271, 27330-27338
39. Harper, A. L.; Skinner, L. M.; Sudol, M.; Katzman, M. Use of patient-derived human immunodeficiency virus type 1 integrases to identify a protein residue that affects target site selection. J. Virol. 2001, 75, 7756-7762
40. Perryman, A. L.; McCammon, J. A. AutoDocking dinucleotides to the HIV-1 integrase core domain: Exploring possible binding sites for viral and genomic DNA. J. Med. Chem. 2002, 45, 5624-5627
41. Pemberton, I. K.; Buckle, M.; Buc, H. The metal ion-induced cooperative binding of HIV-1 integrase to DNA exhibits a marked preference for Mn(II) rather than Mg(II). J. Biol. Chem. 1996, 271, 1498-1506
42. Lee, S. P.; Kim, H. G.; Censullo, M. L.; Han, M. K. Characterization of Mg(2{thorn})-dependent 30-processing activity for human immunodeficiency virus type 1 integrase in vitro: Real-time kinetic studies using fluorescence resonance energy transfer. Biochemistry 1995, 34, 10205-10214
43. Smolov, M.; Gottikh, M.; Tashlitskii, V.; Korolev, S.; Demidyuk, I.; Brochon, J. C.; Mouscadet, J. F.; Deprez, E. Kinetic study of the HIV-1 DNA 30-end processing. FEBS J. 2006, 273, 1137-1151
44. Espeseth, A. S.; Felock, P.;Wolfe, A.;Witmer, M.; Grobler, J.; Anthony, N.; Egbertson, M.; Melamed, J. Y.; Young, S.; Hamill, T.; Cole, J. L.; Hazuda, D. J. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc. Natl. Acad. Sci. USA 2000, 97, 11244-11249
45. Marchand, C.; Zhang, X.; Pais, G. C.; Cowansage, K.; Neamati, N.; Burke, T. R., Jr.,; Pommier, Y. Structural determinants for HIV-1 integrase inhibition by beta-diketo acids. J. Biol. Chem. 2002, 277, 12596-12603
46. Lacroix-Gueu, P. 2007. Imagerie de la dynamique de fluorescence (FLIM, FCS) par excitation a' deux photons pour des études en milieu cellulaire et au sein de biofilms monobactériens. Université Paris-Sud, 2007
47. Bonnenfant, S.; Thomas, C. M.; Vita, C.; Subra, F.; Deprez, E.; Zouhiri, F.; Desmaele, D.; d'Angelo, J.; Mouscadet, J. F.; Leh, H. Styrylquinolines, integrase inhibitors acting prior to integration: A new mechanism of action for anti-integrase agents. J. Virol. 2004, 78, 5728-5736
48. Lataillade, M.; Chiarella, J.; Kozal, M. J. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir. Ther. 2007, 12, 563-570
49. Limon, A.; Devroe, E.; Lu, R.; Ghory, H. Z.; Silver, P. A.; Engelman, A. Nuclear localization of human immunodeficiency virus type 1 preintegration complexes (PICs): V165A and R166A are pleiotropic integrase mutants primarily defective for integration, not PIC nuclear import. J. Virol. 2002, 76, 10598-10607
50. Nissen, P.; Kjeldgaard, M.; Nyborg, J. Macromolecular mimicry. EMBO J. 2000, 19, 489-495
51. Bouyac-Bertoia, M.; Dvorin, J. D.; Fouchier, R. A.; Jenkins, Y.; Meyer, B. E.; Wu, L. I.; Emerman, M.; Malim, M. H. HIV-1 infection requires a functional integrase NLS. Mol. Cell 2001, 7, 1025-1035
52. Dvorin, J. D.; Bell, P.; Maul, G. G.; Yamashita, M.; Emerman, M.; Malim, M. H. Reassessment of the roles of integrase and the central DNA flap in human immunodeficiency virus type 1 nuclear import. J. Virol. 2002, 76, 12087-12096
53. Mousnier, A.; Leh, H.; Mouscadet, J. F.; Dargemont, C. Nuclear import of HIV-1 integrase is inhibited in vitro by styrylquinoline derivatives. Mol. Pharmacol. 2004, 66, 783-788
54. Tsurutani, N.; Kubo, M.; Maeda,Y.; Ohashi, T.;Yamamoto, N.; Kannagi, M.; Masuda, T. Identification of critical amino acid residues in human immunodeficiency virus type 1 IN required for efficient proviral DNA formation at steps prior to integration in dividing and nondividing cells. J. Virol. 2000, 74, 4795-4806
55. Lu, R.; Limon, A.; Devroe, E.; Silver, P. A.; Cherepanov, P.; Engelman, A. Class II integrase mutants with changes in putative nuclear localization signals are primarily blocked at a postnuclear entry step of human immunodeficiency virus type 1 replication. J. Virol. 2004, 78, 12735-12746
56. Arhel, N. J.; Souquere-Besse, S.; Munier, S.; Souque, P.; Guadagnini, S.; Rutherford, S.; Prevost, M. C.; Allen, T. D.; Charneau, P. HIV-1 DNA Flap formation promotes uncoating of the pre-integration complex at the nuclear pore. EMBO J. 2007, 26, 3025-3037.